amfetamine indications/contra

Stem definitionDrug idCAS RN
anorexics 195 300-62-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amphetamine aspartate monohydrate
  • benzadrine
  • amphetamine
  • adderall
  • 1-Benzylethylamine
  • phenedrine
  • (+/-)-1-Phenyl-2-aminopropane
  • amfetamine
  • amphetamine sulfate
  • amphetamine aspartate
  • amphetamine adipate
  • amphetamine resin complex
A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
  • Molecular weight: 135.21
  • Formula: C9H13N
  • CLOGP: 1.74
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -1.89
  • ROTB: 2

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P

Approvals:

DateAgencyCompanyOrphan
Sept. 9, 1955 FDA UCB INC

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 1292.98 46.59 295 1542 18035 3365987
Completed suicide 1272.53 46.59 322 1515 30792 3353230
Toxicity to various agents 1135.78 46.59 321 1516 46733 3337289
Prescribed overdose 686.19 46.59 126 1711 2440 3381582
Poisoning 508.02 46.59 110 1727 5002 3379020
Respiratory arrest 464.58 46.59 119 1718 11249 3372773
Cardiac arrest 440.00 46.59 138 1699 27181 3356841
Cardio-respiratory arrest 364.63 46.59 105 1732 15335 3368687
Drug ineffective 277.83 46.59 149 1688 115941 3268081
Overdose 236.01 46.59 92 1745 33886 3350136
Death 217.23 46.59 140 1697 152184 3231838
Intentional product misuse 206.78 46.59 65 1772 12636 3371386
Exposure via ingestion 198.53 46.59 41 1796 1452 3382570
Product quality issue 194.64 46.59 75 1762 26660 3357362
Inappropriate schedule of drug administration 185.40 46.59 61 1776 13692 3370330
Product substitution issue 145.07 46.59 44 1793 7556 3376466
Disturbance in attention 121.23 46.59 39 1798 8109 3375913
Anxiety 119.90 46.59 60 1777 39569 3344453
Somnolence 116.14 46.59 55 1782 32149 3351873
Aggression 104.68 46.59 38 1799 11347 3372675
Feeling abnormal 102.23 46.59 48 1789 27477 3356545
Insomnia 95.85 46.59 50 1787 35848 3348174
Intentional overdose 87.10 46.59 36 1801 15189 3368833
Agitation 81.31 46.59 37 1800 19669 3364353
Substance abuse 76.33 46.59 18 1819 1174 3382848
Psychotic disorder 72.28 46.59 27 1810 8707 3375315
Drug effect decreased 70.79 46.59 29 1808 11940 3372082
Headache 69.29 46.59 58 1779 91922 3292100
Serotonin syndrome 68.66 46.59 23 1814 5400 3378622
Depression 66.99 46.59 41 1796 39729 3344293

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N06BA01 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:51039 dopamine uptake inhibitor
CHEBI has role CHEBI:35640 adrenergic uptake inhibitor
CHEBI has role CHEBI:35523 bronchodilator agent
FDA EPC N0000175739 Central Nervous System Stimulant
FDA PE N0000175729 Central Nervous System Stimulation
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D001337 Autonomic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Ocular hypertension contraindication 4210003 DOID:9282
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007 DOID:2848
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001 DOID:2349
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050848
Open-angle glaucoma contraindication 84494001 DOID:1067
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:2527
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002 DOID:1826
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007 DOID:6713
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Porphyria contraindication 418470004 DOID:13268
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.89 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 2.5MG BASE/ML DYANAVEL XR TRIS PHARMA INC N208147 Oct. 19, 2015 RX SUSPENSION, EXTENDED RELEASE ORAL Oct. 19, 2018 NEW PRODUCT
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter RELEASING AGENT CHEMBL CHEMBL
Sodium-dependent dopamine transporter Transporter RELEASING AGENT Ki 6.94 PDSP CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.75 PDSP
Cocaine- and amphetamine-regulated transcript protein Transcription factor WOMBAT-PK
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
Trace amine-associated receptor 1 GPCR AGONIST EC50 6.22 SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent dopamine transporter Transporter IC50 6.02 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 4.35 CHEMBL
Transporter Transporter IC50 6.70 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Kd 5.27 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 4.37 CHEMBL
Serotonin (5-HT) receptor GPCR Kd 5.27 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.91 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.12 CHEMBL

External reference:

scroll-->
IDSource
CHEBI:2679 CHEBI
DB00182 DRUGBANK_ID
4019611 VUID
N0000147705 NUI
C0002658 UMLSCUI
4804 IUPHAR_LIGAND_ID
D02074 KEGG_DRUG
CHEMBL405 ChEMBL_ID
CHEMBL501 ChEMBL_ID
6DPV8NK46S UNII
60-13-9 SECONDARY_CAS_RN
4019611 VANDF
725 RXNORM
d00803 MMSL
22672005 SNOMEDCT_US
N0000147705 NDFRT
N0000005864 NDFRT
001790 NDDF
703842006 SNOMEDCT_US
31375 MMSL
CHEMBL1200377 ChEMBL_ID
CHEMBL1200387 ChEMBL_ID
C090411 MESH_SUPPLEMENTAL_RECORD_UI
377 INN_ID
D000661 MESH_DESCRIPTOR_UI
3007 PUBCHEM_CID
1WE PDB_CHEM_ID
FRD PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1491 CAPSULE 7.50 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1491 CAPSULE 7.50 mg ORAL ANDA 21 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0084 TABLET 1.25 mg ORAL ANDA 14 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0084 TABLET 1.25 mg ORAL ANDA 14 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0111 TABLET 2.50 mg ORAL ANDA 14 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0111 TABLET 2.50 mg ORAL ANDA 14 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0401 TABLET 5 mg ORAL ANDA 14 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0401 TABLET 5 mg ORAL ANDA 14 sections